REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?

Key Takeaways Regeneron shares surged 31.5% in six months, driven by pipeline progress and strong earnings.Dupixent growth and label expansions boost revenues, while Eylea faces decline and rising biosimilar pressure.Oncology and new drugs like Libtayo and Lynozyfic support diversification beyond core franchises.The going has been strong for Regeneron Pharmaceuticals (REGN) over the past six months. Shares of this biotech giant have surged 31.5% in this time frame, outpacing the industry’s growth of 13.5%. ...